Effect of VEGF receptor inhibitor PTK787/ZK222548 combined with ionizing radiation on endothelial cells and tumour growth

Abstract

The vascular endothelial growth factor (VEGF) receptor is a major target for anti-angiogenesis-based cancer treatment. Here we report the treatment effect of ionizing radiation in combination with the novel orally bioavailable VEGF receptor tyrosine kinase inhibitor PTK787/ZK222584 on endothelial cell proliferation in vitro and with tumour xenografts in vivo. Combined treatment of human umbilical vein endothelial cells with increasing doses of PTK787/ZK222584 and ionizing radiation abrogated VEGF-dependent proliferation in a dose-dependent way, but inhibition of endothelial cell proliferation was not due to apoptosis induction. In vivo, a combined treatment regimen of PTK787/ZK222584 (4 x 100 mg/kg) during 4 consecutive days in combination with ionizing radiation (4 x 3 Gy) exerted a substantial tumour growth delay for radiation-resistant p53-dysfunctional tumour xenografts derived from SW480 colon adenocarcinoma cells while each treatment modality alone had only a minimal effect on tumour size and neovascularization. SW480 tumours from animals that received a combined treatment regimen, displayed not only an extended tumour growth delay but also a significant decrease in the number of microvessels in the tumour xenograft. These results support the model of a cooperative anti-tumoral effect of angiogenesis inhibitor and irradiation and show that the orally bioavailable VEGF receptor tyrosine kinase inhibitor PTK787/ZK222584 is suitable for combination therapy with irradiation.

References 31

1. 1.

   Asano M., Yukita A., Matsumoto T., Kondo S., Suzuki H. Inhibition of tumor growth and metastasis by an immunoneutralizing monoclonal antibody to human vascular endothelial growth factor/vascular permeability factor121. Cancer Res. 1995;55(22):5296-5301.

   Not in our library

2. 2.

   Borgström P., Hillan K. J., Sriramarao P., Ferrara N. Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: novel concepts of angiostatic therapy from intravital videomicroscopy. Cancer Res. 1996;56(17):4032-4039.

   Not in our library

3. 3.

   Brown L. F., Berse B., Jackman R. W., Tognazzi K., Manseau E. J., Senger D. R., Dvorak H. F. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res. 1993;53(19):4727-4735.

   Not in our library

4. 4.

   Clauss M., Weich H., Breier G., Knies U., Röckl W., Waltenberger J., Risau W. The vascular endothelial growth factor receptor Flt-1 mediates biological activities. Implications for a functional role of placenta growth factor in monocyte activation and chemotaxis. J Biol Chem. 1996;271(30):17629-17634.

   Not in our library10.1074/jbc.271.30.17629 (opens in a new tab)

5. 5.

   Drevs J., Hofmann I., Hugenschmidt H., Wittig C., Madjar H., Müller M., Wood J., Martiny-Baron G., Unger C., Marmé D. Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model. Cancer Res. 2000;60(17):4819-4824.

   Not in our library

6. 6.

   Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995;1(1):27-31.

   Not in our library10.1038/nm0195-27 (opens in a new tab)

7. 7.

   Fong T. A., Shawver L. K., Sun L., Tang C., App H., Powell T. J., Kim Y. H., Schreck R., Wang X., Risau W. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res. 1999;59(1):99-106.

   Not in our library

8. 8.

   Geng L., Donnelly E., McMahon G., Lin P. C., Sierra-Rivera E., Oshinka H., Hallahan D. E. Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. Cancer Res. 2001;61(6):2413-2419.

   Not in our library

9. 9.

   Goldman C. K., Kendall R. L., Cabrera G., Soroceanu L., Heike Y., Gillespie G. Y., Siegal G. P., Mao X., Bett A. J., Huckle W. R. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proc Natl Acad Sci U S A. 1998;95(15):8795-8800.

   Not in our library10.1073/pnas.95.15.8795 (opens in a new tab)

10. 10.

    Gorski D. H., Beckett M. A., Jaskowiak N. T., Calvin D. P., Mauceri H. J., Salloum R. M., Seetharam S., Koons A., Hari D. M., Kufe D. W. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res. 1999;59(14):3374-3378.

    Not in our library

11. 11.

    Gorski D. H., Mauceri H. J., Salloum R. M., Gately S., Hellman S., Beckett M. A., Sukhatme V. P., Soff G. A., Kufe D. W., Weichselbaum R. R. Potentiation of the antitumor effect of ionizing radiation by brief concomitant exposures to angiostatin. Cancer Res. 1998;58(24):5686-5689.

    Not in our library

12. 12.

    Hanahan D., Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996;86(3):353-364.

    Not in our library10.1016/s0092-8674(00)80108-7 (opens in a new tab)

13. 13.

    Joukov V., Kaipainen A., Jeltsch M., Pajusola K., Olofsson B., Kumar V., Eriksson U., Alitalo K. Vascular endothelial growth factors VEGF-B and VEGF-C. J Cell Physiol. 1997;173(2):211-215.

    Not in our library10.1002/(sici)1097-4652(199711)173:2<211::aid-jcp23>3.0.co;2-h (opens in a new tab)

14. 14.

    Kanai T., Konno H., Tanaka T., Baba M., Matsumoto K., Nakamura S., Yukita A., Asano M., Suzuki H., Baba S. Anti-tumor and anti-metastatic effects of human-vascular-endothelial-growth-factor-neutralizing antibody on human colon and gastric carcinoma xenotransplanted orthotopically into nude mice. Int J Cancer. 1998;77(6):933-936.

    Not in our library10.1002/(sici)1097-0215(19980911)77:6<933::aid-ijc23>3.0.co;2-0 (opens in a new tab)

15. 15.

    Kim K. J., Li B., Winer J., Armanini M., Gillett N., Phillips H. S., Ferrara N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 1993;362(6423):841-844.

    Not in our library10.1038/362841a0 (opens in a new tab)

16. 16.

    Kozin S. V., Boucher Y., Hicklin D. J., Bohlen P., Jain R. K., Suit H. D. Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. Cancer Res. 2001;61(1):39-44.

    Not in our library

17. 17.

    Kroll J., Waltenberger J. The vascular endothelial growth factor receptor KDR activates multiple signal transduction pathways in porcine aortic endothelial cells. J Biol Chem. 1997;272(51):32521-32527.

    Not in our library10.1074/jbc.272.51.32521 (opens in a new tab)

18. 18.

    Lund E. L., Bastholm L., Kristjansen P. E. Therapeutic synergy of TNP-470 and ionizing radiation: effects on tumor growth, vessel morphology, and angiogenesis in human glioblastoma multiforme xenografts. Clin Cancer Res. 2000;6(3):971-978.

    Not in our library

19. 19.

    Mauceri H. J., Hanna N. N., Beckett M. A., Gorski D. H., Staba M. J., Stellato K. A., Bigelow K., Heimann R., Gately S., Dhanabal M. Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature. 1998;394(6690):287-291.

    Not in our library10.1038/28412 (opens in a new tab)

20. 20.

    Olofsson B., Korpelainen E., Pepper M. S., Mandriota S. J., Aase K., Kumar V., Gunji Y., Jeltsch M. M., Shibuya M., Alitalo K. Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. Proc Natl Acad Sci U S A. 1998;95(20):11709-11714.

    Not in our library10.1073/pnas.95.20.11709 (opens in a new tab)

21. 21.

    Olofsson B., Pajusola K., Kaipainen A., von Euler G., Joukov V., Saksela O., Orpana A., Pettersson R. F., Alitalo K., Eriksson U. Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Proc Natl Acad Sci U S A. 1996;93(6):2576-2581.

    Not in our library10.1073/pnas.93.6.2576 (opens in a new tab)

22. 22.

    Park J. E., Chen H. H., Winer J., Houck K. A., Ferrara N. Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J Biol Chem. 1994;269(41):25646-25654.

    Not in our library

23. 23.

    Shibuya M. Role of VEGF-flt receptor system in normal and tumor angiogenesis. Adv Cancer Res. 1995;67:281-316.

    Not in our library10.1016/s0065-230x(08)60716-2 (opens in a new tab)

24. 24.

    Shibuya M., Yamaguchi S., Yamane A., Ikeda T., Tojo A., Matsushime H., Sato M. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. Oncogene. 1990;5(4):519-524.

    Not in our library

25. 25.

    Sun L. Q., Li Y. X., Guillou L., Coucke P. A. (E)-2'-deoxy-2'-(fluoromethylene) cytidine potentiates radioresponse of two human solid tumor xenografts. Cancer Res. 1998;58(23):5411-5417.

    Not in our library

26. 26.

    Takahashi T., Shibuya M. The 230 kDa mature form of KDR/Flk-1 (VEGF receptor-2) activates the PLC-gamma pathway and partially induces mitotic signals in NIH3T3 fibroblasts. Oncogene. 1997;14(17):2079-2089.

    Not in our library10.1038/sj.onc.1201047 (opens in a new tab)

27. 27.

    Teicher B. A., Holden S. A., Ara G., Korbut T., Menon K. Comparison of several antiangiogenic regimens alone and with cytotoxic therapies in the Lewis lung carcinoma. Cancer Chemother Pharmacol. 1996;38(2):169-177.

    Not in our library10.1007/s002800050466 (opens in a new tab)

28. 28.

    Terman B. I., Dougher-Vermazen M., Carrion M. E., Dimitrov D., Armellino D. C., Gospodarowicz D., Böhlen P. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun. 1992;187(3):1579-1586.

    Not in our library10.1016/0006-291x(92)90483-2 (opens in a new tab)

29. 29.

    Wood J. M., Bold G., Buchdunger E., Cozens R., Ferrari S., Frei J., Hofmann F., Mestan J., Mett H., O'Reilly T. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res. 2000;60(8):2178-2189.

    Not in our library

30. 30.

    Yamada Y., Nezu J., Shimane M., Hirata Y. Molecular cloning of a novel vascular endothelial growth factor, VEGF-D. Genomics. 1997;42(3):483-488.

    Not in our library10.1006/geno.1997.4774 (opens in a new tab)

31. 31.

    Zaugg K., Rocha S., Resch H., Hegyi I., Oehler C., Glanzmann C., Fabbro D., Bodis S., Pruschy M. Differential p53-dependent mechanism of radiosensitization in vitro and in vivo by the protein kinase C-specific inhibitor PKC412. Cancer Res. 2001;61(2):732-738.

    Not in our library

Cited by papers we hold 1

• Interfering with Tumor Hypoxia for Radiotherapy Optimization · 2021
  No notice

Questions about this paper

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.